Capsaicin, the active ingredient in some pain relieving creams, is an agonist of a non-selective cation channel known as the vanilloid receptor, TRPV1. The pain relieving mechanism of capsaicin includes desensitization of the channel, suggesting that TRPV1 antagonism may be a viable pain therapy approach. In agreement with the above notion, several TRPV1 antagonists have been reported to act as anti-hyperalgesics. Here, we report the in vitro and in vivo characterization of a novel and selective TRPV1 antagonist, AMG 517, and compare its pharmacology with a closely related analogue, AMG8163. Both AMG 517 and AMG8163 potently and completely antagonized capsaicin, proton, and heat activation of TRPV1 in vitro, and blocked capsaicin-induced flinch in rats in vivo. To support initial clinical investigations, AMG 517 was evaluated in a comprehensive panel of toxicology studies that included in vivo assessments in rodents, dogs, and monkeys. The toxicology studies indicated that AMG 517 was generally well tolerated; however, transient increases in body temperature (hyperthermia) were observed in all species following AMG 517 dosing. To further investigate this effect, we tested and showed that the anti-pyretic, acetaminophen, suppressed the hyperthermia caused by TRPV1 blockade. We also showed that repeated administration of TRPV1 antagonists attenuated the hyperthermia response while the efficacy in capsaicin-induced flinch model was maintained. In conclusion, these studies suggest that the transient hyperthermia elicited by TRPV1 blockade may be manageable in the development of TRPV1 antagonists as therapeutics. However, the impact of TRPV1 antagonist-induced hyperthermia on their clinical utility is still unknown.
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Introduction
Pain is a mechanism of the host defense warning system transduced through small diameter nociceptors that signal on-going damage to the body. By its predominant expression in c-fibers, the vanilloid receptor, TRPV1, plays a key role in the detection of noxious painful stimuli such as acid (low pH), noxious heat, components of the "inflammatory soup," vanilloids such as capsaicin (the pungent component of hot chili peppers), and resiniferatoxin (an alkaloid from Ephorbia resinifera) (Caterina et al., 1997; Szallasi and Blumberg, 1999; Holzer, 2004; Szolcsanyi, 2004) . Capsaicin and resiniferatoxin revealed the potential of TRPV1 as a target for pain and helped to identify and clone the TRPV1 channel. Although capsaicin and resiniferatoxin cause burning pain acutely, chronic treatment was shown to produce analgesia through ablation of TRPV1 expressing neurons. These results indicated the potential of TRPV1 agonists as pain therapeutics (reviewed in (Bley, 2004) ).
Up-regulation of TRPV1 has been shown in inflammatory pain models in preclinical species (Ji et al., 2002) and human disease conditions such as inflammatory bowel disease (Matthews et al., 2004) , painful bladder syndromes (Mukerji et al., 2006) , vulvodynia (Tympanidis et al., 2004) , and chronic persistent cough (Groneberg et al., 2004) . In addition, TRPV1 knockout mice showed reduced thermal hypersensitivity after inflammatory tissue injury (Caterina et al., 2000; Davis et al., 2000) and attenuated experimental arthritis (Szabo et al., 2005; Barton et al., 2006) .
Finally, TRPV1 antagonists (that block capsaicin, proton and heat activation) representing various chemotypes acted as anti-hyperalgesics in inflammatory (Pomonis et al., 2003; Valenzano et al., 2003; Walker et al., 2003; Gavva et al., 2005b; Honore et al., 2005; Rami et al., 2006; Gunthorpe et al., 2007) , and surgical-incision (Honore et al., 2005) pain models as well as analgesics in cancer pain (Ghilardi et al., 2005) models (reviewed in (Immke and Gavva, 2006;  This article has not been copyedited and formatted. The final version may differ from this version.
JPET Fast Forward. Published on as DOI: 10.1124 at ASPET Journals on November 7, 2016 jpet.aspetjournals.org Downloaded from Szallasi et al., 2007) ). Taken together, the above data generated strong interest in TRPV1 as a therapeutic target for pain.
Most of the published TRPV1 antagonists lack optimal properties for clinical development such as selectivity, solubility, oral bioavailability, and/or reasonable pharmacokinetics. After evaluation of TRPV1 antagonists representing various chemotypes (Doherty et al., 2005; Xi et al., 2005; Ognyanov et al., 2006; Doherty et al., 2007; Norman et al., 2007) and unpublished data) for potency, selectivity, plasma half-life, effects in the capsaicin-induced flinch model, and efficacy in models of inflammatory pain, we identified AMG 517 as a potential drug for the management of pain in humans. Here, we describe the characterization of AMG 517 and the data set leading to its selection as a clinical candidate.
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Methods
All animal use and husbandry were in accordance with the USDA Animal Welfare Act (9 CFR, Parts 1, 2 and 3) and the Guide for the Care and Use of Laboratory Animals (ILAR publication, 1996, National Academy Press). The cDNA sequences used in this study are identical or similar to AJ277028 (human TRPV1), NP_114188 (rat TRPV1), Q704Y3 (mouse TRPV1), XP_001117609 (Rhesus TRPV1), EF100779 (Cynomolgus TRPV1), Q9WUD2 (rat TRPV2), NP659505 (human TRPV3), NP067638 (human TRPV4), O75762 (human TRPA1) and NP_076985 (human TRPM8).
Agonist-induced 45 Ca 2+ uptake assay. Two days prior to the assay, cells were seeded in Cytostar 96 well plates (Amersham) at a density of 20,000 cells/well. The activation of TRPV1 and TRPV2 was followed as a function of cellular uptake of radioactive calcium ( 45 Ca 2+ , ICN).
Capsaicin (0.5 µM), pH 5, and heat (45 o C) were used as agonists for TRPV1 and 2-APB (200 µM) was used as agonist for TRPV2. All the antagonist 45 Ca 2+ uptake assays were conducted as reported previously (Gavva et al., 2005b) and had a final 45 Ca 2+ concentration of 10 µCi/mL. 
Results
Characterization of AMG 517 as a TRPV1 antagonist
In our efforts to identify a TRPV1 antagonist clinical candidate, we synthesized several novel series of molecules representing various chemotypes ((Doherty et al., 2005; Xi et al., 2005; Ognyanov et al., 2006; Doherty et al., 2007; Norman et al., 2007) ; unpublished data) and evaluated their ability to block various modes of TRPV1 activation. AMG 517 inhibited capsaicin, pH 5, and heat induced 45 Ca 2+ uptake into cells expressing TRPV1 with IC 50 values of 1-2 nM (Table 1, Fig.1A ). AMG 517 blocked capsaicin-, proton-, and heat-induced inward currents in TRPV1 expressing cells similarly (data not shown). In addition, AMG 517 acted as a potent antagonist of all of the endogenous ligands tested ( Table 1) . AMG 517 inhibited native TRPV1 activation by capsaicin in rat dorsal root ganglion neurons with an IC 50 value of 0.68 + 0.2 nM. AMG 517 is a competitive antagonist of both rat and human TRPV1 with dissociation constant (K b ) values of 4.2 and 6.2 nM, respectively ( Fig. 1B-E) . AMG 517 did not activate TRPV1 at concentrations up to 40 µM, as measured by 45 Ca 2+ uptake into TRPV1 expressing cells, indicating that it was not a partial agonist.
Pharmacology of another TRPV1 antagonist, AMG8163 (a 't-butyloxycarbonyl' analogue of AMG 517), used in this study was reported recently (Magal, 2005; Gavva et al., 2007) .
AMG 517 was found to be selective for TRPV1 among the recombinant TRP family members that we have tested ( Fig.2A-E ). The IC 50 value for AMG 517 was >20 µM against 2-APB activated TRPV2 and TRPV3, 4-αPDD activated TRPV4, allyl isothiocyanate activated TRPA1, and icilin activated TRPM8 in cell based assays that measure agonist-induced increases in intracellular calcium in CHO cells recombinantly expressing the appropriate TRP channel. In a selectivity screen conducted by Novascreen ® , 10 µM concentration of AMG 517 showed significant binding (≥ 45% inhibition) to only 3 of 90 evaluated targets that included receptors, enzymes, and ion channels (Supplementary information). AMG 517 showed binding to peripheral monoamine oxidase-B (88%) and site 2 of the sodium ion channel (47%), and showed 79% inhibition of anandamide transport in a functional assay. IC 50 values of 3.4, 11.3, and 19.4 µM were subsequently determined for the monoamine oxidase-B (peripheral), anandamide transporter, and sodium channel (site 2) targets, respectively.
Pharmacokinetic analyses showed that plasma half-life values of AMG 517 were 31, 41, and 62 hrs in rats, dogs, and monkeys, respectively. Oral bioavailability was 47-51% in rats, 23-29% in dogs, and 42-52% in monkeys .
TRPV1 antagonists block capsaicin-induced flinch in rats
Since the pharmacokinetic properties of AMG 517 and its closely related analogue, AMG8163, were amenable to in vivo studies, they were evaluated in a rat capsaicin-induced flinch model as a measure of TRPV1 antagonism (Seabrook et al., 2002) . While oral administration of both AMG 517 and AMG8163 produced a dose-dependent increase in plasma concentrations, they also produced a dose-dependent decrease in the number of flinches induced by capsaicin treatment (Fig. 3A,B and Gavva et al., 2007) . The minimally effective dose (MED), based on a statistically significant difference in number of flinches from the vehicle versus capsaicin administered group, was 0.3 mg/kg (p < 0.05) for AMG 517 and 0.03 mg/kg (p < 0.05) for AMG8163. The corresponding plasma concentrations were 90-100 ng/ml for AMG 517 and approximately 10 ng/ml for AMG8163. Correlating with its long plasma half-life in rats, the time course of AMG 517 (3 mg/kg) exhibited significant reductions in capsaicininduced flinch up to 24 hrs after dosing ( Fig. 3C) . At these time points, plasma levels of AMG To evaluate the effect of repeated dosing with TRPV1 antagonists on capsaicin-induced flinch, 3 mg/kg of AMG8163 was administered twice (p.o.) daily for 4 days. Complete inhibition of the capsaicin-induced flinch response on days 2, 3, and 4 indicated continuous antagonism of TRPV1 by AMG8163 in vivo (Fig. 3D ).
TRPV1 antagonists act as anti-hyperalgesics in rat models of inflammatory pain and cause hyperthermia in rats
Next, we evaluated the ability of AMG 517 and AMG8163 to block pain behavior (thermal hyperalgesia) under inflammatory conditions in rats. Intra-plantar injections of complete Freund's adjuvant (CFA) produced a dose-dependent thermal hyperalgesia indicated by a decrease in paw withdrawal latency in rats, 24 hrs post-injection. TRPV1 antagonists such as AMG9810, A-425619, and BCTC were shown to block hyperalgesia induced by CFA (Pomonis et al., 2003; Gavva et al., 2005b; Honore et al., 2005) . As expected, oral administration of both AMG 517 and AMG8163 reversed established thermal hyperalgesia in a dose-dependent manner at 21 hrs after CFA injection ( Fig. 4A,B ; Fig.1 ). Since most TRPV1
antagonists reported to-date, including AMG 517 and AMG8163, showed only 40-50% block of hyperalgesia in rodent models of pain (reviewed in (Immke and Gavva, 2006) ), we concluded that TRPV1 partially contributes to inflammation-and incision-induced hyperalgesia.
We and others have previously shown that TRPV1 antagonists cause transient hyperthermia in multiple species (rats, dogs, and cynomolgus monkeys). These observations suggested that TRPV1 is tonically activated in naïve rats, dogs, and primates, and that tonic TRPV1 activation regulates body temperature (Bannon, 2004; Swanson et al., 2005; Gavva et al., 2007) . As expected, AMG 517 caused transient hyperthermia in rodents, dogs, and monkeys ( Fig. 4C,D; data not shown). AMG 517 induced hyperthermia in a steep dose dependent manner, with 0.3, 1, and 3 mg/kg associated with 0.5 o C, 0.6 o C, and 1.6 o C increases in body temperature, respectively. Body temperatures of rats treated with all doses of AMG 517 returned to baseline within 10 to 20 hrs. In rats, body temperatures in the vehicle group varied from 37.4 ºC ± 0.05 °C during the light cycle to 37.8 ºC ± 0.05 °C during the dark cycle, suggesting that body temperature is a dynamically regulated process. In monkeys, single doses of AMG 517 at 10 and 30 mg/kg caused an approximate 1 to 1.5 o C increase in body temperature that lasted beyond 24 hours. Mean temperatures in both drug-treated groups differed from the vehicle treated group in a statistically significant manner (ANOVA/Dunnett's) at the majority of evaluated post-dose time-points ( Fig.4D ).
Toxicological evaluation of AMG 517
This article has not been copyedited and formatted. The final version may differ from this version. To support initial clinical investigations, AMG 517 was evaluated in a package of non-clinical toxicology studies that was designed in accordance with relevant regulatory guidelines (ICH, 2000) . Pivotal toxicology studies were conducted in compliance with global Good Laboratory Practice (GLP) regulations, including those defined by the US FDA (21 CFR Part 58).
Individual studies were designed in consideration of relevant regulatory guidelines (refer to cited (selected) guidelines for detail). The package included single dose studies in mice and rats (US-FDA, 1996) , in vitro and in vivo safety pharmacology studies (ICH, 2001) , repeated dose studies in rats, monkeys, and dogs (ICH, 1995; EMEA-CPMP, 2000) , and a standard battery of in vitro and in vivo genetic toxicity studies (ICH, 1997) . AMG 517 was administered p.o. in all in vivo studies. Definitive 28-day repeated-dose studies evaluated daily oral doses up to 500 mg/kg/day in rats and monkeys, producing end-of-treatment Cmax levels of 13,500 ng/mL and 9,160 ng/mL, respectively, at 500 mg/kg/day. Notably, no AMG 517-related adverse effects were observed in any of the above-listed toxicology studies. However, transient drug-related body temperature increases (see below) were noted in mice, rats, dogs, and monkeys.
TRPV1 antagonist-induced hyperthermia attenuates after repeated dosing
To evaluate the effects of repeated dosing on TRPV1 antagonist-induced hyperthermia, we administered AMG8163 twice daily for 4 days to rats implanted with radiotelemetry probes and monitored their body temperature ( Fig. 5A) . Since body temperature measurements were gathered by continuous monitoring we compared the effect of AMG8163 on subsequent days by averaging the temperature from each treatment group for each 24 hour period and ran 4 separate t-tests comparing the AMG8163 treated group to the vehicle treated group. AMG8163 induced a 0.5 to 0.8 ºC increase in body temperature on the first day of treatment that was not apparent by day 4 ( Fig. 5A,B ), suggesting that TRPV1 antagonist-induced hyperthermia attenuates with repeat dosing. Statistically significant differences (2 11 = 2.9; p<0.05) were only apparent on day 1, with average temperature in the vehicle treated group of 37.6 ºC ± 0.12 ºC and average temperature in the AMG8163 treated group equal to 38.1 ºC ± 0.07 ºC (Fig. 5B) .
AMG 517 produced an approximate 1 °C increase in body temperature in both rats and monkeys (Fig. 4C,D and data not shown) . When administered as a single dose, the post-treatment temperature increase was transient, peaking within a few hours and lasting up to 20 hrs. The AMG 517-induced hyperthermic response diminished with repeat dosing in rats (data not shown), dogs (data not shown), and monkeys ( Fig. 5C) , as seen with AMG8163 in rats ( Fig.   5A,B) . In monkeys treated daily for 28 consecutive days, transient increases (up to approximately 1.1 °C greater than controls) in mean body temperature, relative to pre-dose, were observed on Day 1 in all drug treated groups (30, 100, 500 mg/kg/day), with mean temperatures at 3 hours post-dose statistically significantly (p < 0.05) higher than those in the control group.
Following continued repeated dosing, clear drug-related patterns in an effect on body temperature (on days 8, 15, 22, and 28 of the treatment period) were not readily apparent (no other statistically significant differences from controls were observed). This observation suggests that a physiological tolerance develops with repeat dosing in rodents, canines, and nonhuman primates.
TRPV1 antagonist-induced hyperthermia can be suppressed by anti-pyretic acetaminophen Because we predicted that TRPV1 antagonists might produce hyperthermia in humans, we tested whether anti-pyretic acetaminophen could suppress TRPV1 antagonist-induced hyperthermia.
We administered acetaminophen, before and after AMG8163 administration, to rats surgically implanted with radiotelemetry probes. Acetaminophen (300 mg/kg) suppressed the established TRPV1 antagonist-induced hyperthermia, as evidenced by a drop of body temperature from 38.5 °C to 37 °C (Fig. 6A,B) . During baseline telemetry recordings, there was no significant difference among groups (F 3,8 = 3.5, p>0.05) with an average temperature across groups of 36.8 °C ± 0.03 °C. AMG8163-treated rats showed an average temperature of 38.0 °C ± 0.02 °C, while the average temperature in vehicle-treated rats was 37.2 °C ± 0.03 °C, during the 30 to 120 min post dosing phase (t 298 = 21.2, p<0.01). During the 30 to 60 min following acetaminophen administration, average body temperature dropped to 36.4 °C ± 0.04 °C, while the vehicle treated group showed an average temperature of 37. 2 °C ± 0.03 °C (t 148 = 18.3; p<0.01) ( Fig. 6B) .
Acetaminophen reduced the AMG8163-induced body temperature to 37.3 °C ± 0.05 °C, while rats treated with AMG8163 alone had an average temperature of 37.8 °C ± 0.03 °C (t 147 = 9.1; p<0.01). This average temperature in acetaminophen/AMG8163 treated rats temperature is within 0.1 °C of the vehicle-treated group's average temperature (not statistically significant; t 148 = 1.5; p>0.05), but approximately 0.5 °C greater than the average temperature in the vehicle/acetaminophen treated group (t 158 = 15.4; p<0.01) ( Fig. 6B) . Low doses of acetaminophen (100 or 150 mg/kg) that did not drop body temperature by themselves were not effective in reversing AMG8163-induced hyperthermia (data not shown). Acetaminophen's ( Fig. 6A,B) reversal of AMG8163-induced hyperthermia suggests that TRPV1 antagonistinduced hyperthermia could potentially be managed in humans with anti-pyretics, if required. 
Discussion
In the present study, we characterized AMG 517 as a potent TRPV1 antagonist and compared its pharmacology with a closely related analogue, AMG8163, in various in vitro and in vivo assays. Both molecules are potent antagonists of TRPV1 activation by chemical ligands (capsaicin, proposed endogenous agonists, and protons) and heat. Since both AMG 517 and AMG8163 bind the same pocket as capsaicin and block all modes of TRPV1 activation, they represent 'group A' antagonists ( (Gavva et al., 2005a) and data not shown) that lock the channel conformation in a 'closed state. ' We demonstrated the ability of AMG 517 and AMG8163 to block TRPV1 in vivo by showing antagonism of capsaicin-induced flinch in rats and their antihyperalgesic properties through reduction of thermal hyperalgesia in inflammatory pain models (this study and ). Based on its pharmacological activity, favorable pharmacokinetic properties , and favorable non-clinical safety profile in toxicology studies, AMG 517 was chosen for clinical development.
We and others previously showed that TRPV1 antagonists that act as anti-hyperalgesics can cause transient hyperthermia in multiple species (Bannon, 2004; Gavva et al., 2007) for anti-hyperalgesia in models of inflammation. Since AMG 517 is a selective TRPV1 antagonist (IC 50 against closely related TRP channels is >5,000-fold), the hyperthermia and antihyperalgesia were believed to be caused by TRPV1 antagonism alone. Both AMG 517 and AMG8163 are brain penetrant compounds with brain/plasma ratios of 1.01 and 0.58, respectively. As implicated recently (Cui et al., 2006) , the site of action for anti-hyperalgesia by TRPV1 antagonists may be present in the central nervous system, thus requiring higher brain concentrations of antagonists for significant effects.
Although TRPV1 agonists such as capsaicin and resiniferatoxin cause a drop in body temperature (hypothermia), until recently it was not known if TRPV1 is tonically activated in vivo or even if it is involved in body temperature regulation. We recently demonstrated that TRPV1 is tonically activated in vivo based on the fact that antagonists representing a wide variety of chemotypes that block TRPV1 activation by capsaicin, heat, and protons (as well as those that block only capsaicin and heat activation), caused transient hyperthermia through a site of action outside of the blood-brain barrier . Selective antagonists of TRPV1 that cause hyperthermia in multiple species (AMG9810, AMG8163 and several others in rats, JYL1421 in dogs and monkeys ; or JNJ-17203212 in rats (Swanson et al., 2005) and AMG 517 in multiple species [this study]) further demonstrate that TRPV1 is tonically activated in vivo and is involved in body temperature regulation. The fact that AMG 517 caused transient hyperthermia in rats, dogs, and monkeys, further confirms that the involvement of TRPV1 in thermoregulation is conserved across rodents to primates.
The mechanisms of TRPV1 agonist induced hypothermia include skin vasodilation and reduction in metabolic heat production (reviewed in (Hori, 1984) ); whereas the mechanisms of TRPV1 blockade elicited hyperthermia include skin vasoconstriction that reduces heat loss and an increase in metabolic heat production as measured by increased oxygen consumption in rats (Steiner et al., 2007) . In addition, agonist-induced hypothermia and antagonist-induced hyperthermia are absent in TRPV1 knockout mice (Caterina et al., 2000; Steiner et al., 2007) , suggesting that the effects of agonists and antagonists on body temperature are exclusively mediated by TRPV1 channels. Even though TRPV1 is activated by heat, it is not known if TRPV1 itself acts as a thermosensor for the body. It appears that TRPV1 blockade does not affect the thermosensation because thermal preference of TRPV1 antagonist-administered rats was not altered in a thermotaxis gradient assay (Steiner et al., 2007) , suggesting that TRPV1 may not act as a thermosensor in vivo. Interestingly, TRPV3 knockout mice display strong deficits in responses to innocuous and noxious heat in thermotaxis assays, suggesting that TRPV3 acts as a thermosensor (Moqrich et al., 2005; Dhaka et al., 2006) . 
